



Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis

Patrick McMullan^a, Vamadevan S. Ajay ^b, Ravi Srinivas^c, Sandeep Bhalla^d, Dorairaj Prabhakaran^b and Amitava Banerjee ^{e,f,g}

^aUniversity of Birmingham Medical School, Birmingham, UK; ^bHealth System Unit, Centre for Chronic Disease Control, New Delhi, India; ^cResearch and Information Systems for Developing Countries (RIS), New Delhi, India; ^dTraining Division, Public Health Foundation of India, New Delhi, India; ^eUniversity of Birmingham Centre for Cardiovascular Sciences, Birmingham, UK; ^fFarr Institute of Health Informatics Research, University College London, London, UK; ^gSchool of Health, University of Central Lancashire, Preston, UK

ABSTRACT

Background: In India, 50–65% of the population face difficulties in accessing medicines. The Health Impact Fund (HIF) is a novel proposal whereby pharmaceutical companies would be paid based on the measured global health impact of their drugs. We conducted a key stakeholder analysis to explore access to medicines in India, acceptability of the HIF and potential barriers and facilitators at policy level.

Objectives: To conduct a stakeholder analysis of the HIF in India: to determine key stakeholder views regarding access to medicines in India; to evaluate acceptability of the HIF; and to assess potential barriers and facilitators to the HIF as a policy.

Methods: In New Delhi, we conducted semi-structured interviews. There was purposive recruitment of participants with snowball sampling. Transcribed data were analysed using stakeholder analysis frameworks and directed content analysis.

Results: Participation rate was 29% (14/49). 14 semi-structured interviews were conducted among stakeholders in New Delhi. All participants highlighted access to medicines as a problem in India. There were mixed views about the HIF in terms of relevance and scalability. Stakeholders felt it should focus on diseases with limited or no market and potentially incorporate direct investment in research.

Conclusions: First, access to medicines is perceived to be a major problem in India by all stakeholders, but affordability is just one factor. Second, stakeholders despite considerable support for the idea of the HIF, there are major concerns about scalability, generalisability and impact on access to medicines. Third, the HIF and other novel drug-related health policies can afford to be more radical, e.g. working outside the existing intellectual property rights regime, targeting generic as well as branded drugs, or extending to research and development. Further innovations in access to medicines must involve country-specific key stakeholders in order to increase the likelihood of their success.

ARTICLE HISTORY

Received 9 August 2017
Accepted 24 January 2018

RESPONSIBLE EDITOR

John Kinsman, Umeå
University, Sweden.

KEYWORDS

Qualitative; stakeholder
analysis; access to
medicines; policy; India

Background

Inadequate access to medicines accentuates worldwide inequalities in health and income [1,2]. Access is dependent on availability, affordability, quality and proper use, and involves a complex interplay between governments, pharmaceutical companies, individuals and society [3–5]. Access to medicines is a problem across many countries, for both communicable and non-communicable diseases, and at several levels [6–8]. India is the second most populous country in the world with 17% of the world's population but it shoulders 21% of the global disease burden, a major proportion of which requires medicines [9]. However, in 2004, the World Health Organization (WHO) estimated that 50–65% of Indians (499–649 million people) did not have access to even essential medicines [10]. Not only is overall access to medicines limited, but the so-called '70–70 problem' exists, i.e. 70% of Indians' overall medical expenses are

paid upfront and out-of-pocket and 70% of those expenses are on drugs alone [11]. Out-of-pocket drug expenditure pushed 34 million people below the poverty line in 2011 [12].

India has a pharmaceutical industry built upon reverse engineering (analysing products and deducing and developing ways of manufacturing the product from that analysis) and generic production (manufacture of an identical form of the drug to the brand name version) [13]. Since the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement was signed by India in 1994 and fully ratified by 2005, the adoption of product-patent law (where intellectual property rests with the product rather than the process of its production) was required and this reverse engineering/generic production model was discarded. The assumption was that the product-patent model would incentivise greater innovation in the pharmaceutical industry and bring about novel medicines at a

competitive price [4,13–15]. However, research suggests the contrary [13], and TRIPS may instead reduce access to medicines [16], widening global health inequalities [17,18].

Procurement of essential medicines needs to be improved to address these imbalances for ethical [3] and economic reasons [19]. Availability and affordability are both poor in India [20,21]. Dependent on pharmaceutical companies and government [3], they may be improved by more equitable funding. Recent policies to improve healthcare in India have focused on public health infrastructure, universal healthcare coverage, increased health workers in rural settings and reducing out-of-pocket expenditure [16–22]. In relation to access to drugs, the requirements to ‘Improve quality, performance, efficiency, and accountability of public and private health systems’ and ‘Have in place mechanisms to check and control the use of perverse incentives by pharmaceutical and biotechnology companies for health-care providers’ have been recognized as priorities [21–22]. Policies to broaden access to medicines have included the Government of India initiative, ‘Jan Aushadhi’, a countrywide chain of medical stores to make generic and other drugs available at reasonable prices, by bulk purchasing and drug price control, but acceptability and feasibility of these proposals remains unknown.

The issues that face Indian healthcare are complex and multiple actions would be required to make access more equitable [22]. Service delivery, adequate finance, improvements in health information systems and good governance are all considered crucial to healthcare improvement in India, alongside the need to improve drug access [22]. Improved access to medicines requires broadening of access to generic drugs, as well as lowering the cost and improving the supply of patented drugs. The Rashtriya Swasthya Bima Yojna (RSBY) scheme was established by the Government of India in 2008 and aims to provide health insurance cards worth 30,000 rupees (~US\$ 500) per year to all citizens living below the poverty line. National policies such as RSBY and universal healthcare coverage have indirectly aimed to reduce out-of-pocket health expenditure which may improve access to medicines, but no specific national strategy exists to directly improve access to medicines.

Alternative funding for pharmaceutical innovation may offer sustainable and equitable access to novel medicines [17], in the context of declining research and development and stagnant sales [23,24]. The Health Impact Fund (HIF), originally described by philosopher Thomas Pogge and health economist Aidan Hollis in 2008, is an academic policy proposal, stimulated by failure of current reward mechanisms to address access to medicines [25,26]. As a global agency underwritten by governments, the HIF would offer pharmaceutical innovators the option to register

any new product. Registration would entitle the innovator to receive, for a defined period (e.g. 10 years) a share of fixed remuneration from a reward pool. Working within TRIPS [17,27], the HIF would enable pharmaceutical companies to be paid based on the measured global health impact of their drugs [17] (Appendix 1).

The HIF is still in development via an international, interdisciplinary team (including AB as a Medical Advisor and DP as a Scientific Board member). It requires testing of acceptability and feasibility as well as modelling of potential implications before any policy implementation. Global health impact would be predicted based on preliminary trial data (‘efficacy’) and reward would be based on actual impact (‘effectiveness’). The exact nature of global health impact assessment is yet to be finalized, but would require: (i) modelling and extrapolation of trial efficacy data to a particular population at country or regional level; (ii) estimation of ‘real world’ effectiveness using actual outcome data; and (iii) calculation of ‘reward’ based on the impact of the drug (Appendix 2). All firms would have the option to register a new drug with the HIF and, by doing so, must sell the drug at the lowest possible cost, which would be determined by the lowest feasible cost of production and distribution and acceptability of all stakeholders, including governments, payers, patients and pharmaceutical companies [17]. The financial reward would be a portion of pooled resources, financed by governments and other donors, during the drug’s patent [17,28]. The HIF would, theoretically, drive development of drugs that have use in diseases with a high burden worldwide. This may improve access to novel medicines within India, by reducing costs and improving supply. A sum of \$6 billion per year (provided by partner countries supporting the HIF) has been suggested as the minimum amount necessary to allow the HIF to support development of two drugs per annum, sustaining a stock of 20 medicines [27].

Previous surveys and studies have considered access to medicine [29] but the HIF and other proposals to improve access to medicines often lack evidence before implementation, with limited evaluation of proposed benefits. The acceptability of the HIF (which is a policy proposal in development) to key stakeholders is unknown and will affect its feasibility in India and other countries. We therefore conducted the first stakeholder analysis of the HIF as a means for improving access to medicines in India with the following aims:

- (1) To determine key stakeholder views regarding access to medicines in India.
- (2) To evaluate acceptability of the HIF.
- (3) To assess potential barriers and facilitators to the HIF as a policy.

The HIF is intended as a global policy, funded by governments, but this study was designed to specifically assess Indian perspectives in relation to it.

Methods

Design and setting

This study used stakeholder analysis as its primary methodology, defined as ‘a process of systematically gathering and analysing qualitative information to determine whose interests should be taken into account when developing and/or implementing a policy or program’ [30]. Due to time and resource constraints, but also due to the geographic concentration of major stakeholders in Delhi, recruitment was in this setting in India. In consultation with Research and Information Systems for Developing Countries (RIS, which is based within the Ministry of External Affairs, Government of India, and has specific expertise in trade and intellectual property-related matters, including in relation to healthcare) we identified key actors. We divided stakeholders into six categories: pharmaceutical sector, public health, intellectual property law, government, non-governmental organizations (NGOs) and research funding organizations. We explored influence and power by questions focusing on the alliances and resources of the stakeholders [31–33]. Based on inductive interpretation of the interview, stakeholders’ power/influence was categorized for their sector, according to whether they had high or low influence on policy relating to access to medicines (e.g. the HIF), ‘specifically the degree to which they were able to place the issue on the public or political agenda; influence legislation; actively participate in major decision-making fora; and mobilize on this issue’ as per a previous stakeholder analysis [32]. We ensured diversity of stakeholder perspectives in the research setting (New Delhi, India) in order to represent a range of sectors and a spectrum of opinion with respect to the HIF [34]. Ethical approval was obtained from the Independent Ethics Committee at the Centre for Chronic Disease Control, India, and the Internal Research Ethics Committee, University of Birmingham, UK.

Sample

We supplemented purposive recruitment of participants with snowball sampling [34] and used the iterative nature of theoretical sampling [35,36]. Instead, we focused on diversity of recruitment. We initiated recruitment through networks from RIS in Delhi, emailing the Participant Information Sheet and HIF information (Appendix 1), and then snowballed. The information sheet included reasons for this research project and conflicts of interest. Of 49 potential participants contacted, 23 responded (47%). Fourteen face-to-face interviews were conducted in English between 19 February and 5 March

2015 (nine individuals declined due to unwillingness or lack of availability) (Appendix 3). Therefore, overall participation rate was 14/49 (29%).

Data collection

Informed consent was gained from each participant (Appendix 4). No relationship was established with participants prior to study initiation. The interview guide (Appendix 5) was based on literature regarding health policy in India, the HIF and on topics derived from the study aims. It was not pilot tested but agreed by all authors. We conducted semi-structured face-to-face interviews using this stakeholder analysis framework [30], aiming to recruit from each of the six stakeholder groups. Interviews were conducted at the office of the stakeholder or a location convenient for them which would facilitate audio recording. We asked for stakeholder views regarding: access to medicine in India, interest and opinions with respect to the HIF, suggestions for improving access to medicines, as well as potential alliances and resources to translate the HIF into reality. The interviews lasted 20–60 minutes and were all, except one, audio-recorded using a digital tape recorder. Notes were made during the interviews. The interviews were conducted by PM, as a medical student, following basic training in qualitative research at the University of Birmingham and mentorship from senior researchers involved in qualitative research (AB, DP and RS).

Analysis

Following transcription of the recorded interviews, we assessed transcripts for any typographical errors and removed any confidential information. Transcripts were not returned to participants for comment or correction. We used directed content analysis [37] with principal themes of the HIF and access to medicines. In particular, with respect to access, we considered availability (the supply and demand), affordability (the drug price and patients’ ability to pay), accessibility (physical access) and adaptability (the relationship between patients perceptions and what is being offered) as per previous studies of access to medicines [4]. Initially, text relevant to each theme was highlighted. The highlighted passages of text were then coded using pre-determined codes in NVivo 10.0. This process continued until all highlighted data were fully coded. We then conducted a more inductive sub-coding [38], whereby all coded data were sub-coded for further detail. Coding was undertaken by PM and AB.

A reflexive approach was ensured by completion of a diary throughout the process, and the primary researcher (PM) could question interpretations to




Figure 1. Stakeholder analysis matrix comparing the interest of each actor with their perceived power and influence on health policy.

ensure no conflict of interest and bias minimization. Quotations used as evidence in the results have been edited (in terms of syntax) for flow [39]. On the basis of power/influence and interest (classified by the coder) in the HIF in line with previous studies [32], each participant was classified as a ‘defender’ (high interest, low power), ‘bystander’ (low interest, low power), ‘driver’ (high interest, high power) or ‘blocker’ (low interest, high power) with respect to the HIF as a policy (Figure 1). This terminology was developed by AB and PM. A defender would have high motivation to defend the HIF from criticism but low influence. A bystander is low on influence and interest and unlikely to promote or criticize the HIF. A driver is a powerful supporter of the HIF. A blocker is an influential opponent to the HIF. The assigned category was not checked with the participant. The study was designed and reported to meet consolidated criteria for reporting qualitative research (COREQ) [40] and the relevant sections of the COREQ checklist are described in the relevant sections above.

Results

Most stakeholders felt there were significant issues with access to medicines in India, yet their views regarding the proposed HIF were mixed and, although positive in general, there was scepticism with multiple perceived disadvantages. Few stakeholders demonstrated total opposition to the HIF and when opposition was noted, it was focused on

amendment of the HIF rather than the aim of improving access to medicines per se.

Views on access to medicines in India

Access to most citizens is poor and heterogeneous despite a strong domestic pharmaceutical industry

The prevailing idea that access is poor for the majority of Indians was common. Although participants from pharmaceutical and government sectors agreed, they focused on different aspects, for example:

[The pharmaceutical] industry has done remarkably well to meet the country’s need and at prices which are ... I mean you may say compared to Indian income may not be affordable still but if you compare with the world prices these are very, very low prices. (P1; Pharmaceutical; Driver)

The view that the ‘[pharmaceutical] industry has done remarkably well’ is to be expected from a representative of that industry, yet a candid view on the issue with access was still given. The price may be cheap, but even that relatively low price is still, for many, out of reach when the nation ‘has a vast amount of the population which is in the category of absolutely poor or extremely poor ... so whatever price drugs are available ... they won’t be able to purchase these medicines’ (P6; Government; Bystander). Government and ministerial participants corroborated the opinion of the pharmaceutical industry that despite there being issues with affordability, as the public health expert states, the ‘situation is improving significantly with the state governments

taking an active role in expanding free supply of medicines' (P10; Government; Driver). This goes to the heart of access to medicines in India; that healthcare is a state-based issue and there is large inter-state heterogeneity:

Contrast is the name that can be given in many health situations or for that matter any matter of health or any walk of life in India. So in some states there may be reasonably strong access but in some states it may be just not that great. (P9; Public Health; Defender)

Access to medicines includes medicines that are off-patent, and produced by generic companies, as well as those on-patent. Many of the participants referred to overall access being poor but a few highlighted the issue of highly expensive patented medicines.

For example, 'when it comes to medicine and particularly the patented medicines ... it is basically coming from abroad. Most of it is coming from abroad and they have put the prices as very high' (P11; Pharmaceutical; Defender).

The mention of the high cost for patented medicines must be put into the context of the low purchasing power of many Indians. If these 'extremely poor' citizens are unable to purchase any medicines, as participant 6 suggested, then the novel patented medicines are well beyond their purchasing capability. In other words, the scale of the price is less important than the need for free supply of medicine in India.

Branded generics inflate prices

The issue with affordability is not solely with expensive patented medicines but several participants also identified an issue with 'branded generics' (versions of a drug that are bioequivalent to the original product, but are marketed under another company's brand name):

You have had what is known as branded generics ... this is the main challenge I would feel. This is perpetuated because the prescriptions are largely written in brand name and not in generic name ... If prescription is in a brand name then the patient almost

mistakes a brand name for a medicine. (P10; Government; Driver)

This gives rise to a situation where 'access may be stratified on information flow' (P12; Research funder). If the patient is unable to challenge the doctor, who prescribed branded and not generic drugs, due to lack of awareness, then unnecessary higher drug costs ensue, and 'though we have a lot of generics in India, still they are expensive' (P2; Public health; Defender).

Out-of-pocket expenditure dominates

Out-of-pocket expenditure and catastrophic health expenditure were perceived as major issues:

Drugs are meant to be free in public healthcare but are often unavailable and so patients buy out-of-pocket from local shops themselves. (P9; Public Health; Defender)

Lot of our reports ... very clearly indicate that one chronic ailment, one acute case, the person is indebted. He has to sell land and even we have seen family members becoming destitute. (P6; Government; Bystander)

Views on the health impact fund

Table 1, the stakeholder analysis matrix, represents stakeholder opinions with respect to the HIF's policy implementation. The majority (12/14; 86%) of the participants were unaware of the HIF prior to being invited to participate in the research. The stakeholder analysis showed that one participant (P14; NGO) was a potential 'blocker' of the HIF, with four participants classified as 'drivers' (P1; Pharmaceutical; P7; Public health; P10; Government; P13; NGO). Two participants were considered 'bystanders' (P5; NGO; P6; Government) and the remaining seven interviewees were 'defenders'. Other than two individuals, all other participants highlighted affordability as a major determinant of drugs in India. Availability was the second most commonly cited issue (in 9/14). No

Table 1. Stakeholder analysis matrix comparing the interest of each actor in the Health Impact Fund with their perceived power and influence on health policy setting.

PARTICIPANT NUMBER	SECTOR	POWER/INFLUENCE	INTEREST	CATEGORY	DOMAIN OF ACCESS TO MEDICINES			
					availability	affordability	accessibility	adaptability
1	Pharmaceutical	High	High	Driver	x	x		
2	Public Health	Low	High	Defender	x	x	x	
3	IP law	Low	High	Defender	x	x		x
4	Public Health	Low	High	Defender		x	x	
5	NGO	Low	Low	Bystander	x		x	x
6	Government	Low	Low	Bystander	x	x		
7	Public Health	High	High	Driver	x	x		x
8	Research Funding	Low	High	Defender		x		x
9	Public Health	Low	High	Defender	x	x		
10	Government	Low	Low	Driver		x		x
11	Pharmaceutical	Low	High	Defender		x	x	x
12	Research Funding	Low	High	Defender	x	x		
13	NGO	High	High	Driver	x		x	
14	NGO	High	Low	Blocker		x		x

participants listed affordability as the only issue in access to medicines.

Perceived positives of the health impact fund

The underlying aim of the HIF (to increase access to medicines) was generally praised, for example:

For a practising public health professional in India, if you get some superior quality of drug at the lowest price, and assuring its availability, by and large, in a reasonably big way...and there is some regulatory mechanism that which drugs are to be there and which drugs not: that is a dream situation. (P9; Public health; Defender)

But do you think it is feasible? (Interviewer)

But whether it is feasible or not, that is a different issue. (P9; Public health; Defender).

Support for the HIF's ideals, but reservations about its capabilities, were common to many participants.

The frequently held view was that India should, and would, be able to commit to financing such an initiative; for example: 'I am sure the developed countries will put in money and India should not be found lagging behind much' (P10; Government; Driver). This builds on a sense of pride by the Indian nation; to not be 'lagging behind' but to contribute to global initiatives that aim to improve access to medicine. This view was corroborated by other participants: 'there are India, South Africa, Brazil, the BRICS countries... So because they are the emerging donors also... they may be interested in some of these global activities' (P9; Public health; Defender). The view that funding should be possible is encouraging.

Perceived negatives of the health impact fund policy concept

The strongest criticism of the HIF was that it may not have value in the poorest settings 'in countries such as sub-Saharan Africa, for example, where the public health challenges are huge. In fact, you don't require new and innovative drugs, you are just required to improve the health systems over there, use the best available drugs which can make a big change. What would be the role of Health Impact Fund?' (P4; Public health; Defender).

A major concern was that the HIF was too small to have an impact: 'Even this \$6 billion for the HIF, with this looking at diseases with market, to me it does not make sense because this is too modest a figure' (P5; NGO; Bystander).

Moreover, there was scepticism about how impact assessment may actually function:

I don't think the Health Impact Fund is very well fleshed out. How do you sort of define these steps for reward and impact measurement and who pays for it and how does it all go in? (P14; NGO; Blocker)

This Health Impact Fund, they need to do some more work not just with government but have a dialogue with the industry. (P1-Pharmaceutical; Driver)

Perhaps the most interesting critique of the HIF was that, by working within current worldwide intellectual property frameworks, i.e. TRIPS, it was less likely to improve access to medicines:

I am not sure whether this can be a good model because the current patent system is broken... Unless we do something about breaking that monopoly we are not going to see medicines made available. (P2; Public health; Defender).

'...the strong intellectual property regime... would get legitimacy... This has been one of the questions which the Health Impact Fund has always faced, and other proposals have faced.' (P6; Government; Bystander).

The HIF would only offer pharmaceutical companies an alternative; they could still continue monopoly marketing, which was perceived to be against equitable global access to medicines:

'I am not very optimistic of a state instrumentality really solving this problem of the greed of pharma companies to make money.' (P10; Government; Driver)

Indian pharmaceutical representatives argued that a research base must exist in India, in order for funding post-marketing (as outlined in the HIF) to be tenable:

'We don't have experience of developing new original molecules. Therefore, the developing country industry does not have access to these funds' (P1; Pharmaceutical; Driver).

This would create a situation where the HIF may be 'skewed towards big pharma because it seems to be supportive of the big pharma's argument in terms of we innovate and we produce these drugs and so we should get the profits' (P4; Public health; Defender).

Several participants argued that patented medicines were not the priority:

'I am not saying that patented medicines don't have an important role but I am saying that look... problems will exist but you can largely overcome the problems in Indian context by settling the generic medicine pricing and use' (P10; Government; Driver).

Suggestions to alter the health impact fund to best improve access to medicines

Focus on diseases with no market/ neglected diseases

The limited size of the estimated yearly funding pool, \$6 billion, and resulting need for more focus were frequently emphasised:

'Prioritise the areas you want to tackle because there are so many different countries, diversities, demographics and differing needs... as the name suggests "Health Impact Fund", to me you can create impact if you are focused on a few well-chosen priorities' (P13; NGO; Driver).

'If I am the CEO of the Health Impact Fund... I would look at those diseases which could make an impact where industry is unable to do, where there is a market failure... the entire area of neglected diseases requires attention... companies will require to be incentivised to do these trials... Those are areas which I would like to focus because this is not a big amount. It is only 6 billion' (P5; NGO; Bystander).

Fund innovation directly

Indian pharmaceutical companies may lack sufficient research and development capabilities to create new molecules. Amendment of the HIF to offer partial funding of research and development was suggested:

'You must fund research scientists who are working in the lab, as they say from the bench to the bedside, you cannot just focus on the bedside or in between, you have got to focus some [money] on the bench as well. So part of the fund, I think, should be... to kick-start enterprise and research' (P8; Ministry and government sector).

For me the Health Impact Fund is not something that companies will go for. They will probably try and resell something that they already have, to the Health Impact Fund... so offering the money at the end of the chain really doesn't help, it is the work that you do at the beginning of the chain that really makes a difference... Like for example a bio-marker for a TB test that will help you get TB in urine or blood is not something that the companies will do. (P14; International healthcare NGO)

Discussion

This is the first stakeholder analysis regarding the HIF and access to medicines in India. We note three key findings. First, access to medicines is perceived to be a major problem in India by all stakeholders, involving branded and generic drugs and it is not only the problem of pricing, which is the main target of the HIF. Second, although several stakeholders supported the HIF as a vehicle to improve access to medicines, there were major concerns about its scalability, feasibility and impact, mainly because drug pricing alone does not equate to drug access. Third, in order to overcome barriers to the HIF, novel drug-related health policies may need to be more radical, e.g. working outside the existing IP regime, targeting generic as well as branded drugs, or extending to research and development.

A poorly funded public health system drives many Indians to buy branded drugs out-of-pocket and previous research [41] has emphasized

heterogeneity in access [42]. However, it is of great interest that members of all stakeholder groups, including the pharmaceutical sector, feel strongly that the status quo is problematic. In the Global Burden of Disease Study, India ranked 154th among 195 countries for healthcare access and quality [43]; therefore, the problem is wider than access to medicines. Moreover, there is wide regional variation across India in disease burden and disease outcomes [44]. Although there is likely to be support for policies tackling access to medicines, it is unlikely that a single health policy reform (such as the HIF) can tackle all or even most of the problems around access to medicines [45]. Therefore, as the WHO highlights, priority-setting is required [41], and branded medicines may not be the highest priority. In India, generic drugs are a major component of the pharmaceutical market and with the advent of multiple 'fixed-dose combination' preparations (or 'poly-pills'), there is scope for generic or non-patented medications to be included in rewards which are dependent on impact assessment (such as the HIF).

There is stakeholder support for change, but our analysis (Table 1) suggests a wide range of perceived power and interest of stakeholders, even within stakeholder group (e.g. government or NGO) regarding the HIF. Although the majority were in favour rather than against, it is clear that policies which improve access to medicines, whether to gain support of government or the pharmaceutical sector, will require consideration of more than drug affordability. Any policy aiming to tackle access to medicines should be multi-sectoral and involve consultation of multiple, different stakeholders, in order to maximize support and likelihood of success, as well as using available information regarding affordability, availability and other components of access [4]. Reassuringly, several stakeholders felt that the HIF may not be radical enough, suggesting again that policy reform has to be cross-sectoral and cannot be a 'stand-alone' measure. The IP regime was repeatedly highlighted as a barrier to improving access, as was the lack of available funding for research into new molecular entities in India. There are other policy solutions which have been 'field-tested' in India and in other countries, including local pharmaceutical production [46], managed entry agreements [47] and generic drug prioritization [48]. Pharmaceutical policy has been shown to vary by country income, and no policy is likely to be a 'one-size-fits-all' [49]. Before the HIF can be implemented, policy details such as the exact nature of health impact assessment and reward mechanisms need to be finalized. Moreover, research and modelling of the pharmaceutical market (branded versus generic, pre- and post-trial drugs, common versus rare diseases, well-funded versus poorly funded

diseases) are essential to maximize feasibility and ensure credibility [4].

There are several limitations inherent in our study. This was a relatively small qualitative study and only a limited number of stakeholders from each sector were interviewed. The absence of a representative from the Ministry of Finance was a specific limitation that meant data on the feasibility of funding for healthcare initiatives was poor. The stakeholders that participated in the study may have been more interested in the policy, thereby agreeing to an interview, than those who did not reply to the recruiting emails. The participants were all in senior positions and may be somewhat distanced from the 'reality on the ground', but, conversely, these individuals were more likely to have a 'big picture' policy perspective. Perhaps most importantly, the interviewer was a medical student from the UK, who was not experienced in qualitative research, especially in the Indian context, despite appropriate training and mentorship arrangements in the UK and India. Conversely, compared with having an Indian expert or an experienced researcher in access to medicines conducting the research, the bias in interviews was likely to have been minimised.

The stakeholders may have not given detailed analysis on the HIF due to unfamiliarity with its proposals and a potential unwillingness to disregard a potential policy that they have not fully researched, which may introduce bias. However, the framework did enable a detailed appreciation of both each stakeholder's initial views and interest in the policy as well as assessing their power, giving important information to then move the policy forward. We solely focused on the HIF, but the findings may be relevant to development of other policies regarding access to medicines in India with probable relevance but not necessarily generalizability to other countries. The stakeholders and particular barriers and facilitators for access to medicines are country-specific and therefore further studies are needed in other countries. Although two authors (AB and DP) have advisory roles in relation to the HIF, a balanced view was possible and reporting of the mixed views of stakeholders, including concerns about significant limitations show that the risks of bias and conflict of interest were low.

The HIF is one novel solution to the lack of access and innovation in medicines that requires pilot data and field testing. Several international initiatives over the last two decades, including the Gavi (the global vaccine alliance), the Global Fund for TB, Malaria and HIV/AIDS, numerous public-private partnerships and research and development funding schemes have aimed to improve access to medicines for neglected tropical diseases. Compared with these solutions, which have tended to be disease-focused, short-term and vertical in nature, the HIF may offer a system-wide incentive to improve drug innovation based on the

greatest global health impact, but it has its own problems of focusing on drugs rather than health systems, and patented rather than generic drugs.

Conclusion

Access to medicines is perceived to be an important issue in India, requiring urgent policy reform, according to our stakeholder analysis. The Health Impact Fund, a proposal to improve access to medicines by incentivising pharmaceutical companies to produce drugs with the greatest global health impact, is one such suggestion, but may not be far-reaching enough to be successful in its aim of improving access to medicines. The importance of context-specific quantitative and qualitative data (via stakeholder analysis) prior to policy reform and implementation is highlighted by our study.

Acknowledgments

We acknowledge the help of administrative staff at the Centre for Chronic Disease Control, Delhi; University of Birmingham and University of Central Lancashire.

Author contributions

AB conceived the study, and PM and AB formulated the study design. RS, VSA, SB and DP were involved in identification and recruitment of participants. PM conducted interviews and PM and AB were responsible for analysis. PM and AB produced the first draft of the manuscript and all authors contributed to the final draft.

Disclosure statement

AB is Medical Advisor to the Health Impact Fund and DP is on the Scientific Board of the Health Impact Fund. The other authors have no conflict of interest.

Ethics and consent

Ethical approval was obtained from the Independent Ethics Committee at the Centre for Chronic Disease Control, India (IRB0006330) and the Internal Research Ethics Committee, University of Birmingham, UK(2014-2015/C2/DK/05). Informed consent was required from all participants involved in the stakeholder analysis.

Funding information

This work was supported by bursaries from the Wolfson Foundation and the Arthur Thompson Trust. The research has also received funding from the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement no. 339239.

Paper context

Current knowledge: Access to medicines in India requires innovative policies. The Health Impact Fund (HIF) is a potential solution whereby pharmaceutical companies would be paid based on measured health impact of drugs.

Findings: The HIF and other new policies should, at least initially, focus on diseases with limited or no market, and incorporate direct investment in research.

Implications: Policies to improve access to medicines can be more radical, e.g. targeting generic and branded drugs, or extending to research and development.

ORCID

Vamadevan S. Ajay  <http://orcid.org/0000-0002-4102-0505>

Amitava Banerjee  <http://orcid.org/0000-0001-8741-3411>

References

- [1] Chen S, Ravallion M The developing world is poorer than we thought, but no less successful in the fight against poverty. World Bank Policy Research Working Paper WPS 4703 [Internet]; 2008 [cited 2014 Nov 24]. Available from: <http://elibrary.worldbank.org/doi/pdf/10.1596/1813-9450-4703>
- [2] Von Schirnding Y. The world summit on sustainable development: reaffirming the centrality of health. *Global Health*. 2005;1:8.
- [3] Banerjee A. Who has responsibility for access to essential medical drugs in the developing world? *Ethics Econ*. 2006;4:1–23.
- [4] Bigdeli M, Jacobs B, Tomson G, et al. Access to medicines from a health system perspective. *Health Policy Plan*. 2013;28:692–704.
- [5] Wiedenmayer K. Access to medicines. Medicine supply: lessons learnt in Tanzania and Mozambique. Berne, Switzerland: Swiss Agency for Development and Cooperation (SDC); 2004.
- [6] Moye-Holz D, Van Dijk JP, Reijneveld SA, et al. Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country. *Global Health*. 2017;13:53.
- [7] Vialle-Valentin CE, Serumaga B, Wagner AK, et al. Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries. *Health Policy Plan*. 2015;30:1044–1052.
- [8] Kishore SP, Kolappa K, Jarvis JD, et al. Overcoming obstacles to enable access to medicines for noncommunicable diseases in poor countries. *Health Aff (Millwood)*. 2015;34:1569–1577.
- [9] Zodpey S, Pandey A, Murhekar M, et al. Landscaping capacity-building initiatives in epidemiology in India: bridging the demand-supply gap. *WHO South East Asia J Public Health*. 2015;4:204–212.
- [10] Creese A, Gasman N, Mariko M. The world medicines situation. Geneva: World Health Organization; 2004 [cited 2014 Nov 24].
- [11] Ministry of Health and Family Welfare. National health accounts- India. National health counts cell. New Delhi: Government of India; 2009.
- [12] Selvaraj S, Aisola M, Mehta A, et al. An independent evaluation of National Pharmaceutical Pricing Policy 2012 and Drug Prices Control Order 2013. Delhi, India: ISID-PHFI Collaborative Research Programme; 2014.
- [13] Haley GT, Haley UCV. The effects of patent-law changes on innovation: the case of India's pharmaceutical industry. *Technol Forecast Soc Change*. 2012;79:607–619.
- [14] Jung Y, Kwon S. The effects of intellectual property rights on access to medicines and catastrophic expenditure. *Int J Health Serv*. 2015;45:507–529.
- [15] Velasquez G. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property. *Dev World Bioeth*. 2014;14:67–74.
- [16] Reinhardt UE. Can efficiency in health care be left to the market? *J Health Polit Policy Law*. 2001;26:967–992.
- [17] Banerjee A, Hollis A, Pogge T. The Health Impact Fund: incentives for improving access to medicines. *Lancet*. 2010;375:166–169.
- [18] Quick JD. Ensuring access to essential medicines in the developing countries: a framework for action. *Clin Pharmacol Ther*. 2003;73:279–283.
- [19] Deaton A. Health, inequality, and economic development. *J Econ Lit*. 2003;41:113–158.
- [20] Kotwani A. Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all. *BMC Health Serv Res*. 2013;13:285.
- [21] Bansal D, Purohit VK. Accessibility and use of essential medicines in health care: current progress and challenges in India. *J Pharmacol Pharmacother*. 2013;4:13–18.
- [22] Reddy KS, Patel V, Jha P, et al. Towards achievement of universal health care in India by 2020: a call to action. *Lancet*. 2011;377:760–768.
- [23] Munos B. Lessons from 60 years of pharmaceutical innovation. *Nat Rev Drug Discovery*. 2009;8:959–968.
- [24] Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat Rev Drug Discovery*. 2010;9:203–214.
- [25] The Health Impact Fund. Available from: <http://healthimpactfund.org/>
- [26] Pogge T, Hollis A. The Health Impact Fund: making new medicines accessible to all. New Haven: Incentives for Global Health; 2008.
- [27] Hollis A, Pogge T, Singer P, et al. The Health Impact Fund: pay-for-performance. In: Submission to WHO expert group for public health, innovation, and intellectual property. New Haven, USA: Incentives for Global Health; 2009 Apr.
- [28] Banerjee A, Pogge T. The Health Impact Fund: how might it work for novel anticoagulants in atrial fibrillation? *Global Heart*. 2014;9:255–261.
- [29] Newman C, Ajay VS, Srinivas R, et al. Drugs for cardiovascular disease in India: perspectives of pharmaceutical executives and government officials on access and development-a qualitative analysis. *J Pharm Policy Pract*. 2016;9:16.
- [30] Schmeer K. Guidelines for conducting a stakeholder analysis. Washington (DC): Partners for Health Reform; 1999.
- [31] Varvasovszky Z, Brugha R. A stakeholder analysis. *Health Policy Plan*. 2000;15:338–345.
- [32] Knai C, McKee M, Pudule I. Soft drinks and obesity in Latvia: a stakeholder analysis. *Eur J Public Health*. 2011;21:295–299.

- [33] Akinci F, Mollahaliloglu S, Gursoz H, et al. Assessment of the Turkish health care system reforms: a stakeholder analysis. *Health Policy*. 2012;107:21–30.
- [34] Patton MQ. *Qualitative research & evaluation methods*. 3rd ed. Thousand Oaks (CA): Sage; 2002.
- [35] Morse JM. The significance of saturation. *Qual Health Res*. 1995;5:147–149.
- [36] Corbin J, Strauss A. *Basics of qualitative research: grounded theory techniques and procedures*. Newbury Park (CA): Sage; 1990.
- [37] Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. *Qual Health Res*. 2005;15:1277–1288.
- [38] Thomas DR A general inductive approach for qualitative data analysis. 2003; [cited 2015 Apr 28]. Available from: <http://www.frankumstein.com/PDF/Psychology/Inductive%20Content%20Analysis.pdf>
- [39] Sandelowski M. The use of quotes in qualitative research. *Res Nurs Health*. 1994;17:479–482.
- [40] Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*. 2007;19:349–357.
- [41] World Health Organization. Priority Setting for Health Policy and Systems Research in Access to Medicines in India; 2013 [cited 2015 May 1]. Available from: http://www.who.int/alliance-hpsr/projects/alliancehpsr_indiaatmresummary.pdf.pdf?ua=1
- [42] Subramanian SV, Ackerson LK, Subramanyam MA, et al. Health inequalities in India: the axes of stratification. *Brown J World Aff*. 2008;14:127–139.
- [43] Access GBDH, Quality Collaborators. Electronic address cue, Access GBDH, Quality C. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. *Lancet*. 2017;390:231–266.
- [44] Danelich IM, Reed BN, Hollis IB, et al. Clinical update on the management of atrial fibrillation. *Pharmacother J Hum Pharmacol Drug Ther*. 2013;33:422–446.
- [45] Prashanth NS, Elias MA, Pati MK, et al. Improving access to medicines for non-communicable diseases in rural India: a mixed methods study protocol using quasi-experimental design. *BMC Health Serv Res*. 2016;16:421.
- [46] Da Fonseca EM. How can a policy foster local pharmaceutical production and still protect public health? Lessons from the health-industry complex in Brazil. *Glob Public Health*. 2017;13:489–502.
- [47] Ferrario A, Araja D, Bochenek T, et al. The implementation of managed entry agreements in central and Eastern Europe: findings and implications. *Pharmacoeconomics*. 2017;35(12):1271–1285.
- [48] Mathew P. Generic drugs: review and experiences from South India. *J Family Med Prim Care*. 2015;4:319–323.
- [49] Maniadakis N, Kourlaba G, Shen J, et al. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status. *BMC Health Serv Res*. 2017;17:371.

Appendix 1



UNIVERSITY OF
BIRMINGHAM

Research recruitment letter

Dear [insert name],

I am a medical student at the University of Birmingham, United Kingdom, conducting research under the supervision of:

- Dr Amitava Banerjee- Clinical Lecturer in Cardiovascular Medicine at the University of Birmingham and Honorary Specialist Registrar in Cardiology.
- Dr Sachin Chaturvedi- Director-General at the Research and Information System for Developing Countries, a think tank within the Government of India's Ministry of External Affairs.
- Dr Ravi Srinivas- Consultant at the Research and Information System for Developing Countries.
- Dr Ajay Vamadevan- Research Scientist at Public Health Foundation of India (PHFI)

This letter has been sent to you, as you have been identified to be an important stakeholder in the field of access to medicines in India. Your opinions around access to medicines are considered important and sought after.

The research involves an interview with yourself, in which we will discuss access to medicines in India and also talk about a new initiative called the Health Impact Fund. This new initiative aims to create an alternative funding stream for pharmaceutical development, with the overall goal of reducing drug costs and therefore improving access to medicines.

If you agree to participate, all that will be required of you is to have an interview with myself, lasting no longer than 60 minutes. This interview can be at a place and time of convenience to yourself. **Participation is entirely voluntary and all information you give will be dealt with as confidential.** I hope that you can appreciate the importance of the subject matter and your participation would be invaluable and much appreciated.

Should you be interested in participating please contact me at any of the methods detailed below. A more detailed 'Participant information Sheet and consent form' will then be sent to you via email. Should you have any questions, please do not hesitate to contact me.

Yours sincerely,

Patrick McMullan

Email: PXM168@student.bham.ac.uk

Telephone number: 9953690182

The Health Impact Fund:

A cost-effective, feasible plan for improving human health worldwide

At present, the development of new medicines is driven by the reward of temporary market exclusivity. When a new medicine is protected from generic competition, its profit-maximizing price inevitably prevents a large proportion of the world's population – including many in affluent countries – from purchasing it. As a result of this system of incentives, (1) people suffer and die needlessly *and* (2) research is focused on those medicines from which investors can make the most money, rather than on those that would lead to the greatest improvements in human health.

We can clearly do better – but there are also some very difficult problems to be resolved. How do we maintain incentives for innovation if prices are low? And how do we encourage innovators to work on projects that will improve health, rather than merely those that lead to profitable sales? Plausible solutions to these problems can take advantage of the international patent system, but must be more responsive to the health needs of the poor.

The Health Impact Fund (HIF) is the one solution which addresses all these problems.

Financed by governments, the HIF would offer patentees the option to forgo monopoly pricing in exchange for a reward based on the global health impact of their new medicine. By registering a patented medicine with the HIF, a firm would agree to sell it globally at cost. In exchange, the firm would receive, for a fixed time, payments based on the product's assessed global health impact. The arrangement would be optional and it wouldn't diminish patent rights.

The HIF would distribute large sums of money – we propose a minimum level of \$6 billion to be distributed annually. This money would be divided up in proportion to the assessed health impact of each product each year. Thus firms would compete to earn a share of the money by developing and distributing new medicines to obtain the largest possible global health impact. Health impact assessment would be conducted annually by the HIF for each registered medicine.

The HIF has the potential to be an institution that benefits everyone: patients, rich and poor alike, along with their caregivers; pharmaceutical companies and their shareholders; and taxpayers.

How the Health Impact Fund works for patients

The HIF increases the incentives to invest in developing medicines that have high health impact. It directs research toward the medicines that can do the most good. It can also reward the development of new products, and the discovery of new uses for existing products, which the patent system alone can't stimulate because of inadequate protection from imitation. All patients, rich and poor, would benefit from refocusing the innovation and marketing priorities of pharmaceutical companies toward health impact.

Any new medicines and new uses of existing medicines registered for health impact rewards would be available everywhere at marginal cost from the start. Many patients – especially in poor countries, but increasingly in wealthy ones too – are unable to afford the best treatment because it is too expensive. Even if fully insured, patients often lack access to medicines because their insurer deems them too

expensive to reimburse. The HIF solves this problem for registered drugs simply and directly by reducing prices to marginal cost.

How the Health Impact Fund works for Pharmaceutical Companies

Most proposals for increasing access to medicines would reduce the profits of pharmaceutical companies and hence their ability to fund research. The HIF, however, leaves the existing options of pharmaceutical firms untouched. It merely gives them the opportunity to make additional profits by developing new high-impact medicines that would be unprofitable or less profitable under monopoly pricing. Selling such registered medicines at cost, firms won't be forced to defend a policy of charging high prices to poor people and they won't be pressured to make charitable donations. With HIF-registered medicines they can instead "do well by doing good": bring real benefit to patients in a profitable way. Research scientists of these firms will be encouraged to focus on addressing the most important diseases, not merely those that can support high prices.

How the Health Impact Fund works for Taxpayers

The HIF will be supported mainly by governments, which are supported by the taxes they collect. Taxpayers want value for their money, and the HIF provides exactly that. Because the HIF is a more efficient way of incentivizing the pharmaceutical research and development we all want, total expenditures on medicines need not increase. However, if they do, the reason is that new medicines that would not have existed without the HIF are being developed. The HIF mechanism is designed to ensure that taxpayers always obtain value for money in the sense that any product registered with the HIF will have a lower cost for a given amount of health impact than products outside the HIF. Taxpayers may also benefit from a reduction in risks of pandemics and other health problems that easily cross national borders.

The path forward

For the HIF to become a reality, our proposal will need to be studied, challenged, refined, and considered from every angle. We have made a start on formulating the HIF – but we need help from a wide set of stakeholders – innovative companies, governments, insurance companies, epidemiologists, NGOs, lawyers, economists, doctors, and many others too – to push forward with the ideas presented here and to strengthen our proposal. We therefore encourage you to contact us at www.healthimpactfund.org if you have comments or ideas on this proposal.

It is also necessary that governments – supported by their citizens and with the collaboration of pharmaceutical firms – begin making commitments to support the HIF, once they are satisfied of the merits of the proposal. We believe that the right approach is for governments to commit to supporting the HIF financially if enough other countries do so as well.

The Health Impact Fund is a fair and cost-effective way of stimulating research and development of life-saving medicines. It would make advanced medicines available to all at competitive prices, while at the same time offering ample rewards for innovators.

Appendix 2.

Health impact assessment in the HIF (quoted and adapted from Banerjee, A., Hollis, A and Pogge, T. *The Health Impact Fund: incentives for improving access to medicines*. *Lancet*. 2010;375(9709):166–169)

The health impact assessment will draw on the same types of information that agencies such as the National Institute for Health and Clinical Excellence (NICE) now use to make recommendations about listing new drugs, but will aim to update this information with data for use of the drug and information from new practical trials. No method of health impact assessment could be perfect and indisputable in its measurements or the estimates produced from it. However, although these drawbacks are serious, the real comparison is not with a perfect system but with the present situation. In the UK, where drug insurance is universal and NICE assesses the cost-effectiveness of medicines, the present

situation can be viewed as a reward system in which each sale of a drug creates a reward equal to the difference between the price and the cost of manufacture and distribution. The size of the reward per pill is fixed on the basis of information provided to NICE at the time of drug approval, and is typically not modified to show new information. Thus, the UK system is essentially a simple reward system in which the reward equals the price–cost margin multiplied by the number of units sold.

The HIF's health impact assessment would improve on this standard in at least five important ways:

- physician survey data about actual use of medicines
- evidence for drug use in medical practice through practical trials
- patient usage data through surveys of patients who were prescribed the drug
- outcomes data
- data from post-approval phase 4 clinical trials, especially comparative trials.

Appendix 3. Participants

Participant number	Organisation	Sector	Position	Date of interview
P1	Indian Pharmaceutical Alliance	Pharmaceutical	Senior	19/02/2015
P2	Public Health Foundation of India	Public Health	Senior Public Health Specialist and Assistant Professor	19/02/2015
P3	SKS Law Associates (patent law)	IP law	Senior	21/02/2015
P4	Centre for Chronic Disease Control	Public Health	Senior	24/02/2015
P5	Open Source Drug Discovery	NGO	Senior	24/02/2015
P6	Institute for Studies in Industrial Development	Government	Senior	25/2/2015
P7	World Health Organization	Public Health	Senior	26/02/2015
P8	Biotechnology Industry Research Assistance Council (BIRAC)	Research Funding Organization	Senior	01/03/2015
P9	Indian Institute of Public Health	Public Health	Senior	02/03/2015
P10	National Pharmaceutical Pricing Authority	Government	Senior	02/03/2015
P11	Indian Drug Manufacturers Association	Pharmaceutical	Senior	03/03/2015
P12	Wellcome Trust	Research Funding Organization	Senior	04/03/2015
P13	NATHEALTH-Healthcare Foundation of India	NGO	Senior	05/03/2015
P14	Medecin Sans Frontieres	NGO	Senior	05/03/2015

Appendix 4

UNIVERSITY OF
BIRMINGHAM

Participant Information Sheet and Consent form

Title of research: Improving access to medicines in India: a stakeholder analysis

Principal researcher:

Patrick McMullan
Email: PXM168@student.bham.ac.uk
Telephone number: 9953690182

Research supervisors:

- Dr Amitava Banerjee- Clinical Lecturer in Cardiovascular Medicine at the University of Birmingham and Honorary Specialist Registrar in Cardiology.
- Dr Sachin Chaturvedi- Director-General at the Research and Information System for Developing Countries, a think tank within the Government of India's Ministry of External Affairs.
- Dr Ravi Srinivas- Consultant at the Research and Information System for Developing Countries.
- Dr Ajay Vamadevan- Research Scientist at Public Health Foundation of India (PHFI)

Participant Information

Introduction: I am a medical student at the University of Birmingham, United Kingdom, conducting a research project on access to medicines in India. This form will detail the study and what your participation in it will include. Participation is entirely voluntary. After reading this form, should you wish to participate then please contact myself, the principal researcher, as soon as possible. If, at any point, you would like any information clarified or if you have any other questions then please contact me.

Background: You are invited to participate in this study looking at the opinions of key stakeholders on access to medicines in India and on the Health Impact Fund (HIF) as a novel way to increase access to medicines. As an individual who is involved in access to medicines, your opinions are highly valuable to our research. The Health Impact Fund is a market-based solution to improving such access via pay-for-performance mechanisms. It aims to incentivise innovation into diseases not considered profitable under the current funding mechanism for pharmaceutical development and also reduce upfront costs of drugs to patients. All pharmaceutical corporations would have the option of registering a drug with the Health Impact Fund. In doing so, they agree to sell the drug at the lowest possible cost

and instead are paid based on the actual global health impact of their drug, as assessed by the HIF. Governments and other donors would pool resources to finance the HIF. This arrangement would cover the length of time that the drug is on-patent.

Type of research: This study will involve a single face-to-face interview, lasting no longer than 60 minutes, between you and myself.

Participant selection: You are being asked to participate in this study as your opinions are considered highly relevant to access to medicines in India and an assessment of your opinions regarding this and the HIF is sought after.

Voluntary participation: Your participation in this research is entirely voluntary. Even if you decide to participate but later wish to withdraw, this is possible until the data collection component of the research comes to a conclusion on the 10th April 2015. Should you wish to withdraw from the study, please contact myself, the principal researcher, via email or telephone and your interview will be excluded from the analysis and research.

Study procedure: The interview can be conducted at a time and place of convenience to you. However it is requested that this place be quiet and private, if possible, so that we can have an uninterrupted discussion. During the interview, should you desire to not answer any question then do say so and I will simply move on to the next question. The interview will be digitally audio recorded and the recording then transcribed by a professional transcription service. The recording and an anonymised transcription will be treated as confidential and only my supervisors and I will have access to this data. The audio-recordings will be kept on an encrypted USB.

Risks and benefits: No questions of a personal nature are asked, but there is always a risk that you may share some personal or confidential information by chance. Also you may feel uncomfortable talking about some of the topics, for whatever reason. Neither of these are intended so if you feel a question inappropriate you are under no obligation to either answer it or explain why you do not wish to answer it. Again all data is treated with the utmost confidentiality.

There are no direct benefits to taking part, but your participation will give valuable insight into access to medicines in India and give equally valuable information on the HIF as a proposal. This may help formulate policy to improve global access to medicines.

Confidentiality: All data will be treated confidentially. This includes the audio-recording and the interview transcript. Both will be kept electronically secure on an encrypted USB and paper copies kept secure in a locked cabinet. All non-anonymised data will be backed up in encrypted folders on the University of Birmingham Server as well. You will not be referred by your name at all in the study, and all data kept about you will be referenced with a unique ID number and description of your job position in the organisation you work for. This job description will be decided in collaboration with yourself. The table matching your name to ID number will be kept securely in an encrypted folder on a laptop and accessible only by myself.

After the research is completed, Dr Banerjee will keep this data in the secure University of Birmingham server. Any papers, i.e. transcripts and the consent forms, will be scanned then secured digitally by Dr Banerjee also. Long-term storage of these electronic files will be for a period of ten years, after which all data will be deleted.

Results: This research aims to be published in a peer-reviewed journal. Should you wish to receive a summary of the results, inform me via the option on the consent form and it will be emailed to you when completed.

Right to refuse or withdraw: You do not have to take part in this study if you do not wish to do so. At any point during the interview you are allowed to stop it should you desire and you are free to withdraw from the study at any point until data collection is completed by the 10th April 2015. Should you wish to withdraw from the study, please contact myself, the principal researcher, via email or telephone and your interview will be excluded from the analysis and research.

Who to contact: If you desire any points from this information sheet clarified, have any complaints or if you have any other queries relating to the research then please contact myself, the principal researcher or any of my supervisors.

Principal researcher:

Patrick McMullan
Email: PXM168@student.bham.ac.uk
Telephone number: 9953690182

Supervisor contact details:

- Dr Amitava Banerjee- A.Banerjee.1@bham.ac.uk
- Dr Sachin Chaturvedi- dg@ris.org.in
- Dr Ravi Srinivas- ravisrinivas@ris.org.in
- Dr Ajay Vamadevan- ajay@ccdcindia.org

Consent form**Please read the Participant Information Sheet prior to filling out this consent form**

Please read the following statements carefully and tick whether you agree to them, if you wish to ask any questions about this or wish anything clarified then please do ask.

1. Any questions that I may have had on the study have been asked of the researcher and answered to my satisfaction.

2. I agree to participate in this study and I am happy to have an interview with the principal researcher on access to medicines and the Health Impact Fund

3. I give permission for the interview to be audio-recorded and for a transcript to be made of the recording

4. I understand that my details will be anonymised. I agree to be referred to only by a unique ID number and by a job title that I have approved

5. I understand that participation in this study is voluntary, all data will be kept confidentially and that I have the right to leave the study until the 10th April 2015. If I choose to remain then the data collected from the interview will be used in this study and may be used in future studies, with full maintenance of confidentiality.

6. I wish to receive a summary of the research results when the study is completed. This will given via email to the email account this form was sent to, should you prefer it be sent to a different account, please give the address of your preferred email account.

Name of participant [please PRINT] _____

Participant signature _____

Date [dd/mm/yyyy] _____

Researcher signature _____

Date [dd/mm/yyyy] _____

Appendix 5

Interview guide

The main questions are numbered, these questions are to be asked to everyone and are intended as quite open to enable discussion around their content. Particular prompts that may be relevant to expand the main questions are in italics, these may not necessarily be asked but are included as examples to reveal more information that is deemed potentially relevant to the study aims. After question three, a concise explanation of the Health Impact Fund will be read to the participants to ensure that they understand what it is in order for them to answer questions about it.

Access to medicines in India

1. How would you describe overall access to medicines in India?
 - *Present state of affairs- better or worse than the past? Why? Examples of past policies which were good or bad for access to medicines?*
 - *Is access the same for everyone? If not- what personal characteristics do you believe access to medicines is stratified along? Are there geographical or institutional stratifications?*
 - *If believe access is poor, why? If believe access is good, why?*
 - *Are the challenges in access to medicine unique to India or global? What unique challenges might India face?*
2. Are you aware of any ideas, concepts or policies which aim to improve access to medicines?
 - *If so, what are they?*
 - *How did you hear about them?*
3. Have you, prior to being invited to participate in this study, ever heard of the Health Impact Fund?
 - *If so, how did you hear about it?*

The Health Impact Fund is a market-based solution to improving access to medicines via pay-for-performance mechanisms. It aims to incentivise innovation into diseases not considered profitable under the current funding mechanism for pharmaceutical development and also reduce upfront costs of drugs to patients. All pharmaceutical corporations would have the option of registering a drug with the Health Impact Fund. In doing so, they agree to sell the drug at the lowest possible cost and instead are paid based on the actual global health impact of their drug, as assessed by the HIF. Governments and other donors would pool resources to finance the HIF. This arrangement would cover the length of time that the drug is on-patent. It is estimate that an initial pool of \$6 billion would be allocated annually and divided up in a proportion based on the global health impact of the drug that year.

Position on and interest of the Health Impact Fund

4. What are your initial opinions on the Health Impact Fund as a policy idea?
 - *Overall positive, why? Overall negative, why?*
 - *Which aspects of it do you like or dislike?*
 - *Do you consider it a feasible policy idea? Why/why not?*
5. What are the potential benefits to you and your organisation of the Health Impact Fund?
 - *If individual is not aligned with a particular organisation then here will instead focus on the potential benefits they believe the Health Impact Fund may confer to overall public health*
 - *For each benefit, please explain.*
 - *Why do you think it would benefit you?*
 - *Is it the whole concept that would benefit you or particular aspects of it? If are particular aspects, what are they?*
6. What are the potential disadvantages to you and your organisation of the Health Impact Fund?
 - *If individual is not aligned with a particular organisation then here will instead focus on the potential disadvantages they believe the Health Impact Fund may confer to overall public health*
 - *For each disadvantage, please explain.*
 - *Why do you think it would disadvantage you?*
 - *Is it the whole concept that would disadvantage you or particular aspects of it? If are particular aspects, what are they?*
7. Will there be any public health implications from implementing the Health Impact Fund?
 - *Any other social implication?*
8. Based on our discussions of both your initial opinions of the Health Impact Fund and on the benefits/disadvantages it may confer to you and your organisation, how would you overall describe your position on the Health Impact Fund as a policy idea?

Influence, resources and alliances

9. You describe overall support of/opposition to the Health Impact Fund but under what conditions would you choose to instead oppose/support it?
 - *Are there any such conditions?*
 - *If so, what are they?*
 - *Are they likely to occur?*
10. Having described your overall position on the Health Impact Fund, in what manner would you demonstrate your support or opposition to this proposed policy?
 - *Would you publicly support/oppose it?*
 - *What steps would you take to support/oppose it?*
 - *How would you practically support/oppose it?*

11. What conditions would have to be present for you to express this support/opposition?
12. Would you take the initiative in supporting or opposing the Health Impact Fund or would you wait for others to do so?
 - *Why? Who are these 'others'?*
13. What resources would your organisation have to dedicate to supporting/opposing the Health Impact Fund?
 - *Financial, political, technological or human?*
 - *Are these resources secure long-term or likely to change?*
14. How quickly would you be able to mobilise these resources to support/oppose the Health Impact Fund?
 - *Both your organisations ability overall to mobilise them and your ability within your organisation.*
15. Are there any other organisation or individuals that you would ally with in your support of/opposition to the Health Impact Fund?
 - *Do you currently collaborate with them?*
 - *Why do you feel you could ally yourself with them?*
 - *How would this alliance work?*
 - *How would you practically go about forming this alliance*